Phage therapy for hard-to-treat bacterial infections
Part of Infections clinical trials.
This study looks at how well phage therapy works for people with stubborn bacterial infections, like NTM. If your doctor is already considering phage therapy as part of your care, this trial may help track your response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a bacterial or mycobacterial infection that requires treatment
- Your doctor is considering phage therapy as part of your standard care
- You are willing and able to take part in study procedures
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This study looks at how nutrition and immune cell activity relate to the progression of lung disease caused by nontuberculous mycobacteria (NTM). It may help doctors better understand and monitor this chronic infection.
This study looks at the community of tiny organisms in the lungs (the lung microbiome) in people with bronchiectasis caused by NTM (non-tuberculous mycobacteria). It compares people with positive NTM cultures to people without, to better understand what’s going on in the lungs and why symptoms may differ.
This trial tests whether bacteriophages—viruses that kill bacteria—can help treat a chronic lung infection caused by a drug-resistant bacterium called Mycobacterium abscessus.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
Hear when a new Nontuberculous Mycobacterial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.